Nimotuzumab combined with cisplatin plus fluorouracil chemotherapy in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: A multicentre, open-label, phase II clinical trial.

Chong Zhao,Jingjing Miao,Guanzhu Shen,Jin‐Gao Li,Ning Zhang,Mei-Shi,Lin Wang,Guo Qing Hu,Xiaozhong Chen,Xuefeng Hu,Shi Xiu Wu,Jiaxin Chen,Xunfan Shao,Conghua Xie

Nimotuzumab combined with cisplatin plus fluorouracil chemotherapy in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: A multicentre, open-label, phase II clinical trial.

2017

Chong Zhao
Jingjing Miao
Guanzhu Shen
Jin‐Gao Li
Ning Zhang
Mei-Shi
Lin Wang
Guo Qing Hu
Xiaozhong Chen
Xuefeng Hu
Shi Xiu Wu
Jiaxin Chen
Xunfan Shao
Conghua Xie

6028Background: Cisplatin plus fluorouracil (PF) is main therapy for metastatic nasopharyngeal carcinoma (NPC). However, the efficacy is not satisfactory, especially in patients with metastasis aft...

Keywords:

Clinical trial
Cisplatin
Nimotuzumab
Fluorouracil
Nasopharyngeal carcinoma
Cancer research
Pathology
Radiation therapy
Chemotherapy
Medicine
Metastasis
Oncology
in patient
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations